Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pembrolizumab May Induce Sarcoid-Like Skin Reactions

Marilynn Larkin  |  May 12, 2017

NEW YORK (Reuters Health)—Eruptive keatoacanthomas and extensive panniculitus are among the dermatological conditions associated with the anticancer agent pembrolizumab, researchers say. Pembrolizumab, a humanized IgG4 PD-1 (programmed cell death-1) antagonist antibody, is an immune checkpoint inhibitor (CPI) approved in the U.S. for treating advanced melanoma, non-small-cell lung cancer and head and neck squamous cell carcinoma….

How Gout Patients Can Stay on Target with the Go for Six Campaign

Karen Appold  |  May 12, 2017

Gout patients need to lower their uric acid levels to 6.0 mg/dL or below and maintain that level. According to N. Lawrence Edwards, MD, MACP, MACR, an education campaign has been raising awareness of this fact and helping gout patients…

Aetna Fully Exits Obamacare Exchanges with Pull-Out in 2 States

Deena Beasley  |  May 11, 2017

(Reuters)—Health insurer Aetna Inc said on Wednesday it will exit the 2018 Obamacare individual insurance market in Delaware and Nebraska – the two remaining states where it offered the plans. Aetna had already said it would exit the individual commercial market in Virginia and Iowa, after pulling out of several other states last year. Aetna…

Cracking, Popping Joints May Foretell Arthritis

Carolyn Crist  |  May 11, 2017

(Reuters Health)—Grating, cracking or popping sounds around joints may predict future arthritis, especially in the knees, according to a recent U.S. study. Among thousands of people with no knee pain who were followed for three years, one quarter had noisy knees yet they made up three quarters of the cases of symptomatic knee arthritis that…

Pricey Arthritis Drug Effective in Small Fraction of Ulcerative Colitis Cases

Gene Emery  |  May 9, 2017

NEW YORK (Reuters Health)—Pfizer’s expensive arthritis drug tofacitinib has been shown to produce a remission in nearly 1 in 5 patients with moderate to severe ulcerative colitis, but long-term remission persists in fewer than half of those cases. In a series of studies published in the May 4 New England Journal of Medicine, researchers reported…

U.S. Democrats Criticize Senate’s All-Male Healthcare Group

John Whitesides & Sarah N. Lynch  |  May 9, 2017

WASHINGTON (Reuters)—U.S. Democrats on Sunday criticized the lack of women on a working group in the Republican-led Senate that will craft a plan to pass legislation to repeal and replace Obamacare. As the Senate begins to wrestle with a Republican healthcare bill narrowly approved by the House of Representatives last week, senators questioned why the…

Pregabalin Is Ineffective for Sciatica

Lara C. Pullen, PhD  |  May 8, 2017

A recent small-scale study examined the efficacy of pregabalin in the treatment of neuropathic pain caused by sciatica, as well as its associated low back pain. Researchers found the treatment did not reduce leg pain better than placebo and resulted in more adverse events…

Republican Moves on Obamacare Cloud Insurers’ 2018 Plans

Caroline Humer  |  May 5, 2017

NEW YORK (Reuters)—U.S. Republicans may be moving ahead with a vote to repeal Obamacare, but the uncertainty about what a national health law may look like is clouding insurers’ decisions on whether to stay in the individual insurance market in 2018. Republicans do plan to vote on the U.S. House of Representatives bill, the American…

Arthritis Awareness Month: 5 Ways to Get Involved

From the College  |  May 4, 2017

In early March, the Centers for Disease Control and Prevention (CDC) released a new report showing that the number of Americans living with arthritis is at an all-time high. According to the report, 54 million Americans now live with arthritis, and approximately 79 million will have arthritis by 2040. This stark picture comes at a…

CMS Notifying Clinicians of Their MIPS Status

From the College  |  May 4, 2017

According to the Centers for Medicare & Medicaid Services (CMS), the Medicare Administrative Contractors (MACs) that process Medicare Part B claims have begun informing providers of their participation status in the Merit-Based Incentive Payment System (MIPS). This information is coming in the form of hard-copy letters that started mailing in late April and will continue…

  • « Previous Page
  • 1
  • …
  • 205
  • 206
  • 207
  • 208
  • 209
  • …
  • 317
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences